Estonia
2006: Reimbursement of anti-dementia drugs
All four anti-dementia drugs are authorised for use in Estonia and with the exception of rivastigmine, they are part of the reimbursement system and reimbursed at 50%.
Alzheimer Europe was unable to obtain detailed information on the specific conditions for reimbursement in Estonia and existing access restrictions.
Last Updated: Wednesday 15 July 2009
